1041434-82-5 | Peramivir trihydrate

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$7.00	$5.00
50mg	98%	in stock	$13.00	$9.00
250mg	98%	in stock	$20.00	$14.00
1g	95%	in stock	$65.00	$46.00

Description

• Catalog Number: AE11311
• Chemical Name: Peramivir trihydrate
• CAS Number: 1041434-82-5
• Molecular Formula: C15H34N4O7
• Molecular Weight: 382.4531
• MDL Number: MFCD09837902
• SMILES: CCC([C@@H]([C@H]1[C@H](NC(=N)N)C[C@@H]([C@H]1O)C(=O)O)NC(=O)C)CC.O.O.O

Computed Properties

• Complexity: 460
• Covalently-Bonded Unit Count: 4
• Defined Atom Stereocenter Count: 5
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 8
• Rotatable Bond Count: 7

Literature

• Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans.

  Journal of clinical pharmacology 20120901

• Recent advances in neuraminidase inhibitor development as anti-influenza drugs.

  ChemMedChem 20120901

• Efficacy of a single intravenous dose of the neuraminidase inhibitor peramivir in the treatment of equine influenza.

  Veterinary journal (London, England : 1997) 20120801

• In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20120801

• In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.

  The Journal of antimicrobial chemotherapy 20120801

• Editorial commentary: What did we learn from the emergency use authorization of peramivir in 2009?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120701

• Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120701

• Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120701

• Neuropathology of H5N1 virus infection in ferrets.

  Veterinary microbiology 20120504

• Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.

  Antiviral research 20120401

• Peramivir for the treatment of influenza.

  Expert review of anti-infective therapy 20120201

• Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09.

  PloS one 20120101

• Drugs: Lines of defence.

  Nature 20111207

• The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.

  Bioorganic & medicinal chemistry letters 20111201

• Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration.

  The Annals of pharmacotherapy 20111201

• [Clinical efficiency in children treated with intravenous drip infusion of peramivir].

  The Japanese journal of antibiotics 20111201

• Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11.

  Emerging infectious diseases 20111101

• Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme.

  Antiviral research 20110901

• Postpartum pharmacokinetics of peramivir in the treatment of 2009 H1N1 influenza.

  Obstetrics and gynecology 20110801

• Use of intravenous neuraminidase inhibitors during the 2009 pandemic: results from population-based surveillance.

  JAMA 20110713

• A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice.

  Antiviral research 20110401

• Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110315

• Peramivir: another tool for influenza treatment?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110315

• Successful salvage therapy with inhaled zanamivir in a patient with peramivir-resistant pandemic influenza A (H1N1) 2009 virus.

  Scandinavian journal of infectious diseases 20110201

• The emergency use authorization of peramivir IV: a view from the manufacturer.

  Clinical pharmacology and therapeutics 20110201

• Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.

  The Journal of infectious diseases 20110101

• Economic model for emergency use authorization of intravenous peramivir.

  The American journal of managed care 20110101

• Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses.

  PloS one 20110101

• Synergistic effects in the designs of neuraminidase ligands: analysis from docking and molecular dynamics studies.

  Journal of theoretical biology 20101207

• Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model.

  Antiviral research 20101201

• Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.

  Transplant infectious disease : an official journal of the Transplantation Society 20101201

• A fourth scale sensitive to the magnetic field; intermolecular frequency symmetry in a specific interaction between protein and low-molecular compound.

  Chemical & pharmaceutical bulletin 20101201

• The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir.

  Clinical pharmacology and therapeutics 20101101

• Peramivir for severe influenza infection in a patient with diabetic nephropathy.

  American journal of respiratory and critical care medicine 20101101

• Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.

  Antiviral research 20101001

• Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy.

  Pharmacotherapy 20101001

• Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.

  Journal of medicinal chemistry 20100909

• [Current anti-influenza virus chemotherapy].

  Nihon rinsho. Japanese journal of clinical medicine 20100901

• Treatment options for H5N1: lessons learned from the H1N1 pandemic.

  Postgraduate medicine 20100901

• Peramivir clearance in continuous renal replacement therapy.

  Hemodialysis international. International Symposium on Home Hemodialysis 20100701

• Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.

  The Journal of antimicrobial chemotherapy 20100601

• Peramivir and its use in H1N1 influenza.

  Drugs of today (Barcelona, Spain : 1998) 20100601

• Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: Detection of extrapulmonary H1N1 RNA and use of intravenous peramivir.

  Annals of internal medicine 20100504

• Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100501

• Losing the opportunity to study influenza drugs.

  JAMA 20100303

• [Research progress of anti-influenza virus agents].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100301

• Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.

  Antiviral research 20100201

• [Emergency admission of peramivir in the U.S.A].

  Pharmazie in unserer Zeit 20100101

• Intravenous peramivir emergency use authorization 2009: update for the clinical nurse specialist.

  Clinical nurse specialist CNS 20100101

• Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.

  The Annals of pharmacotherapy 20100101

• Pandemic (H1N1) 2009-associated ARDS rescued by neuraminidase inhibitors with emergency use of extracorporeal membrane oxygenation.

  Internal medicine (Tokyo, Japan) 20100101

• Fulminant fatal swine influenza (H1N1): Myocarditis, myocardial infarction, or severe influenza pneumonia?

  Heart & lung : the journal of critical care 20100101

• Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.

  Antiviral therapy 20100101

• Successful management of fulminant influenza A subtype H1N1 myocarditis.

  BMJ case reports 20100101

• Emergency-use authorization of peramivir.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20091215

• The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.

  The New England journal of medicine 20091203

• Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.

  Journal of chemical information and modeling 20091001

• Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.

  Antiviral research 20090701

• Quantification of peramivir (a novel anti-influenza drug) in human plasma by hydrophilic interaction chromatography/tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090401

• Developing new antiviral agents for influenza treatment: what does the future hold?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090101

• Development and validation of a high-throughput zwitterionic hydrophilic interaction liquid chromatography solid-phase extraction-liquid chromatography-tandem mass spectrometry method for determination of the anti-influenza drug peramivir in plasma.

  Journal of chromatography. A 20081226

• Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice.

  Antiviral research 20081101

• Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.

  Proteins 20080601

• Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1).

  Virology 20080425

• Neuraminidase inhibitor resistance in influenza viruses.

  Journal of medical virology 20071001

• Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.

  Antiviral research 20070501

• Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.

  Antiviral research 20070301

• Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20061215

• [Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza].

  Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20061201

• Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection.

  Antiviral research 20060801

• Anti-influenza virus activity of peramivir in mice with single intramuscular injection.

  Antiviral research 20060101

• Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.

  Antiviral therapy 20060101

• Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo.

  Bioorganic & medicinal chemistry 20050602

• Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.

  Antiviral therapy 20050101

• A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.

  Antiviral therapy 20040801

• Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.

  Virus research 20040701

• Inhibition of influenza virus infections in immunosuppressed mice with orally administered peramivir (BCX-1812).

  Antiviral research 20030901

• Stereoselective total synthesis of racemic BCX-1812 (RWJ-270201) for the development of neuraminidase inhibitors as anti-influenza agents.

  The Journal of organic chemistry 20030822

• A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding.

  Antiviral research 20030601

• Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers.

  AAPS pharmSci 20021201

• A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site.

  The Journal of general virology 20021101

• Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza.

  Expert opinion on investigational drugs 20020601

• Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.

  Antiviral research 20020601

• Structural studies of the resistance of influenza virus neuramindase to inhibitors.

  Journal of medicinal chemistry 20020523

• Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin.

  Chemotherapy 20020501

• Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA.

  The Journal of infectious diseases 20020301

• Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.

  Antiviral research 20020101

• RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza.

  Philosophical transactions of the Royal Society of London. Series B, Biological sciences 20011229

• Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.

  Journal of medicinal chemistry 20011206

• Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201.

  Antiviral research 20011201

• Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.

  Antimicrobial agents and chemotherapy 20011201

• Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.

  Antimicrobial agents and chemotherapy 20011001

• Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201.

  Antiviral research 20010901

• Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice.

  International immunopharmacology 20010601

• Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.

  Antimicrobial agents and chemotherapy 20010401

• Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities.

  Antimicrobial agents and chemotherapy 20010301

• In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201.

  Antimicrobial agents and chemotherapy 20010301

• BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.

  Journal of medicinal chemistry 20000921